Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Status regarding Novo Nordisk's holding of its own shares (30 September 2017)


Posted on: 02 Oct 17

Bagsværd, Denmark, 2 October 2017 - In continuation of the company's announcements dated 3 May 2017 and 9 August 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2017 owned 41,621,013 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 8,324,203 or 1.7% of the total share capital.

In the third quarter of 2017 a total of 14,842,082 B shares were repurchased, and 3,418 B shares were disposed to employees in connection with employee incentive programmes.

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 76 / 2017 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/24eb336d-84a7-4c0e-a320-1d7402746b58

GlobeNewswire
globenewswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.